Zealand Financial Statements From 2010 to 2025
| ZEAL Stock | DKK 558.00 20.50 3.54% |
Check Zealand Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zealand Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Zealand financial statements analysis is a perfect complement when working with Zealand Pharma Valuation or Volatility modules.
Zealand |
Zealand Pharma AS Company Shares Owned By Insiders Analysis
Zealand Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Zealand Pharma Shares Owned By Insiders | 0.07 % |
Most of Zealand Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zealand Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 0.07% of Zealand Pharma AS are shares owned by insiders. This is 99.54% lower than that of the Healthcare sector and 99.51% lower than that of the Biotechnology industry. The shares owned by insiders for all Denmark stocks is 99.31% higher than that of the company.
Zealand Pharma AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zealand Pharma's current stock value. Our valuation model uses many indicators to compare Zealand Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zealand Pharma competition to find correlations between indicators driving Zealand Pharma's intrinsic value. More Info.Zealand Pharma AS is rated fourth in return on equity category among its peers. It is rated fourth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Zealand Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Zealand Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Zealand Pharma Financial Statements
Zealand Pharma investors utilize fundamental indicators, such as revenue or net income, to predict how Zealand Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.
Pair Trading with Zealand Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zealand Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zealand Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Zealand Stock
Moving against Zealand Stock
| 0.72 | LASP | Laan Spar Bank | PairCorr |
| 0.69 | JYSK | Jyske Bank AS | PairCorr |
| 0.69 | SCHO | Schouw | PairCorr |
| 0.65 | NDA-DK | Nordea Bank Abp | PairCorr |
| 0.63 | DONKEY | Donkeyrepublic Holding | PairCorr |
The ability to find closely correlated positions to Zealand Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zealand Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zealand Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zealand Pharma AS to buy it.
The correlation of Zealand Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zealand Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zealand Pharma AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zealand Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.